New ALS Therapies and Platform Trial Signal Turning Point for Treatment

James Harrington MPH, Health & Biotech Journalist

✨ Why this is good news

New research is bringing real hope for treating ALS, a severe disease that damages nerve cells and leads to muscle weakness.

Tofersen for SOD1 ALS.Before, there were no treatments targeting the genetic cause of ALS. Now, this FDA-approved drug can slow disease progression for the 2% of patients with an SOD1 mutation, proving precision medicine works.
Platform trial acceleration.Traditional trials test one drug at a time, which is slow. The new platform model tests multiple therapies simultaneously against a shared placebo group, speeding up discovery for all patients.
Shift from generic to targeted.Historically, ALS treatments were one-size-fits-all with limited effect. The success of tofersen validates a new approach of developing drugs for specific patient subgroups, paving the way for more.
Momentum for more therapies.With one targeted drug approved and an efficient trial system running, researchers describe a historic turning point. This creates a clear pathway to develop and test the next generation of treatments.

Researchers and clinicians describe a historic turning point in the fight against amyotrophic lateral sclerosis (ALS), driven by new targeted therapies and an innovative clinical trial model accelerating drug discovery.

This optimism follows the 2023 FDA approval of tofersen (Qalsody), a medication designed for the approximately 2% of ALS patients with a specific mutation in the SOD1 gene. The drug represents a significant shift towards precision medicine in neurology, showing it can slow disease progression for this subset of patients. "We're hoping this will be the first of many more treatments targeted to genetic mutations or other specific mechanisms," says Dr. Sabrina Paganoni, a specialist at the Healey and AMG Center for ALS.

A major engine for this progress is the HEALEY ALS Platform Trial, launched in 2020. This collaborative model tests multiple drug candidates simultaneously against a shared placebo group, dramatically speeding up the research process. So far, more than 1,300 people have participated across over 70 U.S. sites, with seven drugs evaluated. The platform has already helped advance two promising therapies to the next phase of testing.

Next Steps in Research and Patient Access

Building directly on the platform trial's findings, a new Phase 3 study called PREVAiLS is set to begin recruiting in early 2026. It will test the drug pridopidine in people with early, rapidly progressive ALS, focusing on slowing functional decline and prolonging survival. Alongside this trial, an expanded access program will offer pridopidine to some patients not eligible for the clinical study, providing early access and collecting further safety data.

Parallel efforts aim to build foundational resources for future breakthroughs. A national research consortium established in 2023, ALL ALS, is working to create the largest dataset and biosample repository from people living with ALS or at genetic risk. Meanwhile, separate research into brain-computer interface technology, like the BrainGate Consortium, continues to explore how implanted devices could restore communication and control for those who have lost physical function.

With multiple pathways of investigation now yielding results, the landscape for ALS is shifting from one of management to one of tangible, targeted intervention, offering renewed hope to patients and families.

This article is for informational purposes only and does not constitute medical advice. The information presented is based on published research and official announcements. Always consult a qualified healthcare professional before making any medical decisions.